Impact Of Pd-L Ligands And Indoleamine 2,3-Dioxygenase On Prognosis And Survival Of Diffuse Large B-Cell Lymphoma

Background. Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin B-cell lymphoma and one of the most chemosensitive malignant diseases. Modern risk-adapted treatment regimens lead to a good control of the disease and high cure rate. However, 30-40% of patients are resistant to standard and salvage chemotherapeutic regimens. New therapeutic methods are needed to improve the outcome. Currently, a lot of studies are aimed to identify the interplay between immune system and tumor for some newly revealed potential biomarkers.